#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=The microbial community that lives in the human body , called the microbiota , consists of a large variety of microorganisms including bacteria , viruses , fungi , eukaryotes and archae .
1-1	0-3	The	abstract[1]	new[1]	coref	11-48[112_1]
1-2	4-13	microbial	abstract[1]	new[1]	_	_
1-3	14-23	community	abstract[1]	new[1]	_	_
1-4	24-28	that	_	_	_	_
1-5	29-34	lives	_	_	_	_
1-6	35-37	in	_	_	_	_
1-7	38-41	the	place[2]	new[2]	_	_
1-8	42-47	human	place[2]	new[2]	_	_
1-9	48-52	body	place[2]	new[2]	_	_
1-10	53-54	,	_	_	_	_
1-11	55-61	called	_	_	_	_
1-12	62-65	the	object[3]	new[3]	coref	5-9[29_3]
1-13	66-76	microbiota	object[3]	new[3]	_	_
1-14	77-78	,	_	_	_	_
1-15	79-87	consists	_	_	_	_
1-16	88-90	of	_	_	_	_
1-17	91-92	a	abstract[4]	new[4]	_	_
1-18	93-98	large	abstract[4]	new[4]	_	_
1-19	99-106	variety	abstract[4]	new[4]	_	_
1-20	107-109	of	abstract[4]	new[4]	_	_
1-21	110-124	microorganisms	abstract[4]|abstract[5]	new[4]|new[5]	coref	6-40[0_5]
1-22	125-134	including	abstract[4]|abstract[5]	new[4]|new[5]	_	_
1-23	135-143	bacteria	abstract[4]|abstract[5]|animal	new[4]|new[5]|new	coref	7-20
1-24	144-145	,	abstract[4]|abstract[5]	new[4]|new[5]	_	_
1-25	146-153	viruses	abstract[4]|abstract[5]|object	new[4]|new[5]|new	_	_
1-26	154-155	,	abstract[4]|abstract[5]	new[4]|new[5]	_	_
1-27	156-161	fungi	abstract[4]|abstract[5]|object	new[4]|new[5]|new	_	_
1-28	162-163	,	abstract[4]|abstract[5]	new[4]|new[5]	_	_
1-29	164-174	eukaryotes	abstract[4]|abstract[5]|animal	new[4]|new[5]|new	_	_
1-30	175-178	and	abstract[4]|abstract[5]	new[4]|new[5]	_	_
1-31	179-185	archae	abstract[4]|abstract[5]|animal	new[4]|new[5]|new	_	_
1-32	186-187	.	_	_	_	_

#Text=Every human being harbors between 10 trillion and 100 trillion microbial cells , which is approximately equal to 10 times the total number of body cells .
2-1	188-193	Every	place[11]	new[11]	_	_
2-2	194-199	human	place[11]	new[11]	_	_
2-3	200-205	being	place[11]	new[11]	_	_
2-4	206-213	harbors	place[11]	new[11]	_	_
2-5	214-221	between	place[11]	new[11]	_	_
2-6	222-224	10	place[11]|quantity[12]	new[11]|new[12]	_	_
2-7	225-233	trillion	place[11]|quantity[12]	new[11]|new[12]	_	_
2-8	234-237	and	place[11]	new[11]	_	_
2-9	238-241	100	place[11]|object[13]	new[11]|new[13]	coref	2-25[16_13]
2-10	242-250	trillion	place[11]|object[13]	new[11]|new[13]	_	_
2-11	251-260	microbial	place[11]|object[13]	new[11]|new[13]	_	_
2-12	261-266	cells	place[11]|object[13]	new[11]|new[13]	_	_
2-13	267-268	,	_	_	_	_
2-14	269-274	which	_	_	_	_
2-15	275-277	is	_	_	_	_
2-16	278-291	approximately	_	_	_	_
2-17	292-297	equal	_	_	_	_
2-18	298-300	to	_	_	_	_
2-19	301-303	10	time[14]	new[14]	_	_
2-20	304-309	times	time[14]	new[14]	_	_
2-21	310-313	the	quantity[15]	new[15]	_	_
2-22	314-319	total	quantity[15]	new[15]	_	_
2-23	320-326	number	quantity[15]	new[15]	_	_
2-24	327-329	of	quantity[15]	new[15]	_	_
2-25	330-334	body	quantity[15]|object[16]	new[15]|giv[16]	coref	3-10[20_16]
2-26	335-340	cells	quantity[15]|object[16]	new[15]|giv[16]	_	_
2-27	341-342	.	_	_	_	_

#Text=The term microbiome refers to the gene set of these microbial cells .
3-1	343-346	The	abstract[17]	new[17]	coref	4-1[22_17]
3-2	347-351	term	abstract[17]	new[17]	_	_
3-3	352-362	microbiome	abstract[17]	new[17]	_	_
3-4	363-369	refers	_	_	_	_
3-5	370-372	to	_	_	_	_
3-6	373-376	the	abstract[19]	new[19]	_	_
3-7	377-381	gene	abstract|abstract[19]	new|new[19]	coref	18-7
3-8	382-385	set	abstract[19]	new[19]	_	_
3-9	386-388	of	abstract[19]	new[19]	_	_
3-10	389-394	these	abstract[19]|object[20]	new[19]|giv[20]	_	_
3-11	395-404	microbial	abstract[19]|object[20]	new[19]|giv[20]	_	_
3-12	405-410	cells	abstract[19]|object[20]	new[19]|giv[20]	_	_
3-13	411-412	.	_	_	_	_

#Text=The gut microbiome is estimated to contain over 150 times more genes than the human genome .
4-1	413-416	The	abstract[22]	giv[22]	_	_
4-2	417-420	gut	abstract|abstract[22]	new|giv[22]	coref	5-9
4-3	421-431	microbiome	abstract[22]	giv[22]	_	_
4-4	432-434	is	_	_	_	_
4-5	435-444	estimated	_	_	_	_
4-6	445-447	to	_	_	_	_
4-7	448-455	contain	_	_	_	_
4-8	456-460	over	quantity[23]	new[23]	_	_
4-9	461-464	150	quantity[23]	new[23]	_	_
4-10	465-470	times	quantity[23]	new[23]	_	_
4-11	471-475	more	abstract[24]	new[24]	_	_
4-12	476-481	genes	abstract[24]	new[24]	_	_
4-13	482-486	than	abstract[24]	new[24]	_	_
4-14	487-490	the	abstract[24]|object[25]	new[24]|new[25]	_	_
4-15	491-496	human	abstract[24]|object[25]	new[24]|new[25]	_	_
4-16	497-503	genome	abstract[24]|object[25]	new[24]|new[25]	_	_
4-17	504-505	.	_	_	_	_

#Text=During long-standing interactions , a mutual co-evolution between gut microbiota and the host occurs , with the former making an important contribution to human metabolism , with significant effects on the anatomical , physiological , and immunological development of the host .
5-1	506-512	During	_	_	_	_
5-2	513-526	long-standing	abstract[26]	new[26]	coref	11-41[108_26]
5-3	527-539	interactions	abstract[26]	new[26]	_	_
5-4	540-541	,	_	_	_	_
5-5	542-543	a	abstract[27]	new[27]	_	_
5-6	544-550	mutual	abstract[27]	new[27]	_	_
5-7	551-563	co-evolution	abstract[27]	new[27]	_	_
5-8	564-571	between	abstract[27]	new[27]	_	_
5-9	572-575	gut	abstract[27]|abstract|object[29]|abstract[30]	new[27]|giv|giv[29]|new[30]	coref|coref|coref	6-14[40_29]|7-12|12-8[121_30]
5-10	576-586	microbiota	abstract[27]|object[29]|abstract[30]	new[27]|giv[29]|new[30]	_	_
5-11	587-590	and	abstract[27]|abstract[30]	new[27]|new[30]	_	_
5-12	591-594	the	abstract[27]|abstract[30]|person[31]	new[27]|new[30]|new[31]	coref	5-40[36_31]
5-13	595-599	host	abstract[27]|abstract[30]|person[31]	new[27]|new[30]|new[31]	_	_
5-14	600-606	occurs	_	_	_	_
5-15	607-608	,	_	_	_	_
5-16	609-613	with	_	_	_	_
5-17	614-617	the	_	_	_	_
5-18	618-624	former	_	_	_	_
5-19	625-631	making	_	_	_	_
5-20	632-634	an	abstract[32]	new[32]	_	_
5-21	635-644	important	abstract[32]	new[32]	_	_
5-22	645-657	contribution	abstract[32]	new[32]	_	_
5-23	658-660	to	abstract[32]	new[32]	_	_
5-24	661-666	human	abstract[32]|abstract[33]	new[32]|new[33]	_	_
5-25	667-677	metabolism	abstract[32]|abstract[33]	new[32]|new[33]	_	_
5-26	678-679	,	_	_	_	_
5-27	680-684	with	_	_	_	_
5-28	685-696	significant	abstract[34]	new[34]	_	_
5-29	697-704	effects	abstract[34]	new[34]	_	_
5-30	705-707	on	abstract[34]	new[34]	_	_
5-31	708-711	the	abstract[34]|abstract[35]	new[34]|new[35]	_	_
5-32	712-722	anatomical	abstract[34]|abstract[35]	new[34]|new[35]	_	_
5-33	723-724	,	abstract[34]|abstract[35]	new[34]|new[35]	_	_
5-34	725-738	physiological	abstract[34]|abstract[35]	new[34]|new[35]	_	_
5-35	739-740	,	abstract[34]|abstract[35]	new[34]|new[35]	_	_
5-36	741-744	and	abstract[34]|abstract[35]	new[34]|new[35]	_	_
5-37	745-758	immunological	abstract[34]|abstract[35]	new[34]|new[35]	_	_
5-38	759-770	development	abstract[34]|abstract[35]	new[34]|new[35]	_	_
5-39	771-773	of	abstract[34]|abstract[35]	new[34]|new[35]	_	_
5-40	774-777	the	abstract[34]|abstract[35]|person[36]	new[34]|new[35]|giv[36]	_	_
5-41	778-782	host	abstract[34]|abstract[35]|person[36]	new[34]|new[35]|giv[36]	_	_
5-42	783-784	.	_	_	_	_

#Text=Considering that many bacterial species still cannot be cultured , our understanding of gut microbiota has evolved over the past few years thanks to the availability of advanced molecular methods that permit us to identify a large quantity of microorganisms .
6-1	785-796	Considering	_	_	_	_
6-2	797-801	that	_	_	_	_
6-3	802-806	many	plant[37]	new[37]	coref	22-28[223_37]
6-4	807-816	bacterial	plant[37]	new[37]	_	_
6-5	817-824	species	plant[37]	new[37]	_	_
6-6	825-830	still	_	_	_	_
6-7	831-837	cannot	_	_	_	_
6-8	838-840	be	_	_	_	_
6-9	841-849	cultured	_	_	_	_
6-10	850-851	,	_	_	_	_
6-11	852-855	our	person|abstract[39]	acc|new[39]	ana	6-33
6-12	856-869	understanding	abstract[39]	new[39]	_	_
6-13	870-872	of	abstract[39]	new[39]	_	_
6-14	873-876	gut	abstract[39]|object[40]	new[39]|giv[40]	coref	7-11[51_40]
6-15	877-887	microbiota	abstract[39]|object[40]	new[39]|giv[40]	_	_
6-16	888-891	has	_	_	_	_
6-17	892-899	evolved	_	_	_	_
6-18	900-904	over	_	_	_	_
6-19	905-908	the	_	_	_	_
6-20	909-913	past	_	_	_	_
6-21	914-917	few	_	_	_	_
6-22	918-923	years	time	new	_	_
6-23	924-930	thanks	_	_	_	_
6-24	931-933	to	_	_	_	_
6-25	934-937	the	abstract[42]	new[42]	_	_
6-26	938-950	availability	abstract[42]	new[42]	_	_
6-27	951-953	of	abstract[42]	new[42]	_	_
6-28	954-962	advanced	abstract[42]|abstract[43]	new[42]|new[43]	_	_
6-29	963-972	molecular	abstract[42]|abstract[43]	new[42]|new[43]	_	_
6-30	973-980	methods	abstract[42]|abstract[43]	new[42]|new[43]	_	_
6-31	981-985	that	_	_	_	_
6-32	986-992	permit	_	_	_	_
6-33	993-995	us	person	giv	_	_
6-34	996-998	to	_	_	_	_
6-35	999-1007	identify	_	_	_	_
6-36	1008-1009	a	abstract[45]	new[45]	ana	7-3[0_45]
6-37	1010-1015	large	abstract[45]	new[45]	_	_
6-38	1016-1024	quantity	abstract[45]	new[45]	_	_
6-39	1025-1027	of	abstract[45]	new[45]	_	_
6-40	1028-1042	microorganisms	abstract[45]|abstract	new[45]|giv	_	_
6-41	1043-1044	.	_	_	_	_

#Text=Today , it is known that although 98 % of the gut microbiota is composed of four phyla of bacteria ( Firmicutes , Bacteroidetes , Proteobacteria and Actinobacteria ) , the majority are either Firmicutes or Bacteroidetes .
7-1	1045-1050	Today	time	new	_	_
7-2	1051-1052	,	_	_	_	_
7-3	1053-1055	it	abstract	giv	_	_
7-4	1056-1058	is	_	_	_	_
7-5	1059-1064	known	_	_	_	_
7-6	1065-1069	that	_	_	_	_
7-7	1070-1078	although	_	_	_	_
7-8	1079-1081	98	quantity[49]	new[49]	_	_
7-9	1082-1083	%	quantity[49]	new[49]	_	_
7-10	1084-1086	of	quantity[49]	new[49]	_	_
7-11	1087-1090	the	quantity[49]|object[51]	new[49]|giv[51]	coref	8-10[65_51]
7-12	1091-1094	gut	quantity[49]|abstract|object[51]	new[49]|giv|giv[51]	coref	8-11
7-13	1095-1105	microbiota	quantity[49]|object[51]	new[49]|giv[51]	_	_
7-14	1106-1108	is	_	_	_	_
7-15	1109-1117	composed	_	_	_	_
7-16	1118-1120	of	_	_	_	_
7-17	1121-1125	four	abstract[52]	new[52]	appos	7-22[55_52]
7-18	1126-1131	phyla	abstract[52]	new[52]	_	_
7-19	1132-1134	of	abstract[52]	new[52]	_	_
7-20	1135-1143	bacteria	abstract[52]|animal	new[52]|giv	coref	21-18[213_0]
7-21	1144-1145	(	_	_	_	_
7-22	1146-1156	Firmicutes	substance|abstract[55]	new|giv[55]	_	_
7-23	1157-1158	,	abstract[55]	giv[55]	_	_
7-24	1159-1172	Bacteroidetes	abstract[55]|object	giv[55]|new	_	_
7-25	1173-1174	,	abstract[55]	giv[55]	_	_
7-26	1175-1189	Proteobacteria	abstract[55]|object	giv[55]|new	_	_
7-27	1190-1193	and	abstract[55]	giv[55]	_	_
7-28	1194-1208	Actinobacteria	abstract[55]|animal	giv[55]|new	coref	29-32[281_0]
7-29	1209-1210	)	_	_	_	_
7-30	1211-1212	,	_	_	_	_
7-31	1213-1216	the	substance[59]	new[59]	coref	7-34[60_59]
7-32	1217-1225	majority	substance[59]	new[59]	_	_
7-33	1226-1229	are	_	_	_	_
7-34	1230-1236	either	substance[60]	giv[60]	_	_
7-35	1237-1247	Firmicutes	substance[60]	giv[60]	_	_
7-36	1248-1250	or	substance[60]	giv[60]	_	_
7-37	1251-1264	Bacteroidetes	substance[60]|object	giv[60]|new	_	_
7-38	1265-1266	.	_	_	_	_

#Text=With this premise , in the last decade , the gut microbiota has become a key topic in the investigation of several gastrointestinal ( GI ) as well as extra-GI diseases .
8-1	1267-1271	With	_	_	_	_
8-2	1272-1276	this	abstract[62]	new[62]	_	_
8-3	1277-1284	premise	abstract[62]	new[62]	_	_
8-4	1285-1286	,	_	_	_	_
8-5	1287-1289	in	_	_	_	_
8-6	1290-1293	the	time[63]	new[63]	_	_
8-7	1294-1298	last	time[63]	new[63]	_	_
8-8	1299-1305	decade	time[63]	new[63]	_	_
8-9	1306-1307	,	_	_	_	_
8-10	1308-1311	the	object[65]	giv[65]	coref	12-8[120_65]
8-11	1312-1315	gut	abstract|object[65]	giv|giv[65]	coref	9-22
8-12	1316-1326	microbiota	object[65]	giv[65]	_	_
8-13	1327-1330	has	_	_	_	_
8-14	1331-1337	become	_	_	_	_
8-15	1338-1339	a	_	_	_	_
8-16	1340-1343	key	_	_	_	_
8-17	1344-1349	topic	_	_	_	_
8-18	1350-1352	in	_	_	_	_
8-19	1353-1356	the	abstract[66]	new[66]	_	_
8-20	1357-1370	investigation	abstract[66]	new[66]	_	_
8-21	1371-1373	of	abstract[66]	new[66]	_	_
8-22	1374-1381	several	abstract[66]	new[66]	_	_
8-23	1382-1398	gastrointestinal	abstract[66]	new[66]	_	_
8-24	1399-1400	(	_	_	_	_
8-25	1401-1403	GI	abstract	new	_	_
8-26	1404-1405	)	_	_	_	_
8-27	1406-1408	as	_	_	_	_
8-28	1409-1413	well	_	_	_	_
8-29	1414-1416	as	_	_	_	_
8-30	1417-1425	extra-GI	abstract[68]	new[68]	_	_
8-31	1426-1434	diseases	abstract[68]	new[68]	_	_
8-32	1435-1436	.	_	_	_	_

#Text=Irritable bowel syndrome ( IBS ) is a common functional clinical condition characterized by abdominal discomfort or pain and alteration of gut habits without an underlying structural pathology .
9-1	1437-1446	Irritable	abstract[70]	new[70]	appos	9-5[0_70]
9-2	1447-1452	bowel	object|abstract[70]	new|new[70]	_	_
9-3	1453-1461	syndrome	abstract[70]	new[70]	_	_
9-4	1462-1463	(	_	_	_	_
9-5	1464-1467	IBS	abstract	giv	coref	9-8[72_0]
9-6	1468-1469	)	_	_	_	_
9-7	1470-1472	is	_	_	_	_
9-8	1473-1474	a	abstract[72]	giv[72]	coref	10-2[0_72]
9-9	1475-1481	common	abstract[72]	giv[72]	_	_
9-10	1482-1492	functional	abstract[72]	giv[72]	_	_
9-11	1493-1501	clinical	abstract[72]	giv[72]	_	_
9-12	1502-1511	condition	abstract[72]	giv[72]	_	_
9-13	1512-1525	characterized	_	_	_	_
9-14	1526-1528	by	_	_	_	_
9-15	1529-1538	abdominal	abstract[73]	new[73]	_	_
9-16	1539-1549	discomfort	abstract[73]	new[73]	_	_
9-17	1550-1552	or	_	_	_	_
9-18	1553-1557	pain	abstract	new	coref	11-35
9-19	1558-1561	and	_	_	_	_
9-20	1562-1572	alteration	abstract[75]	new[75]	_	_
9-21	1573-1575	of	abstract[75]	new[75]	_	_
9-22	1576-1579	gut	abstract[75]|abstract|object[77]	new[75]|giv|new[77]	coref	11-41
9-23	1580-1586	habits	abstract[75]|object[77]	new[75]|new[77]	_	_
9-24	1587-1594	without	abstract[75]|object[77]	new[75]|new[77]	_	_
9-25	1595-1597	an	abstract[75]|object[77]|abstract[78]	new[75]|new[77]|new[78]	_	_
9-26	1598-1608	underlying	abstract[75]|object[77]|abstract[78]	new[75]|new[77]|new[78]	_	_
9-27	1609-1619	structural	abstract[75]|object[77]|abstract[78]	new[75]|new[77]|new[78]	_	_
9-28	1620-1629	pathology	abstract[75]|object[77]|abstract[78]	new[75]|new[77]|new[78]	_	_
9-29	1630-1631	.	_	_	_	_

#Text=As IBS affects 9 – 23 % of the general population , with considerable impact on quality of life and health care resource utilization , it represents an important medical challenge in term of diagnosis and treatment .
10-1	1632-1634	As	_	_	_	_
10-2	1635-1638	IBS	event	giv	ana	10-26
10-3	1639-1646	affects	_	_	_	_
10-4	1647-1648	9	quantity[80]	new[80]	_	_
10-5	1649-1650	–	quantity[80]	new[80]	_	_
10-6	1651-1653	23	quantity[80]|quantity[81]	new[80]|new[81]	_	_
10-7	1654-1655	%	quantity[80]|quantity[81]	new[80]|new[81]	_	_
10-8	1656-1658	of	quantity[80]|quantity[81]	new[80]|new[81]	_	_
10-9	1659-1662	the	quantity[80]|quantity[81]|person[82]	new[80]|new[81]|new[82]	_	_
10-10	1663-1670	general	quantity[80]|quantity[81]|person[82]	new[80]|new[81]|new[82]	_	_
10-11	1671-1681	population	quantity[80]|quantity[81]|person[82]	new[80]|new[81]|new[82]	_	_
10-12	1682-1683	,	_	_	_	_
10-13	1684-1688	with	_	_	_	_
10-14	1689-1701	considerable	abstract[83]	new[83]	_	_
10-15	1702-1708	impact	abstract[83]	new[83]	_	_
10-16	1709-1711	on	abstract[83]	new[83]	_	_
10-17	1712-1719	quality	abstract[83]|abstract[84]	new[83]|new[84]	_	_
10-18	1720-1722	of	abstract[83]|abstract[84]	new[83]|new[84]	_	_
10-19	1723-1727	life	abstract[83]|abstract[84]|abstract	new[83]|new[84]|new	_	_
10-20	1728-1731	and	abstract[83]|abstract[84]	new[83]|new[84]	_	_
10-21	1732-1738	health	abstract[83]|abstract[84]|abstract[88]	new[83]|new[84]|new[88]	_	_
10-22	1739-1743	care	abstract[83]|abstract[84]|abstract|abstract[88]	new[83]|new[84]|new|new[88]	_	_
10-23	1744-1752	resource	abstract[83]|abstract[84]|abstract|abstract[88]	new[83]|new[84]|new|new[88]	_	_
10-24	1753-1764	utilization	abstract[83]|abstract[84]|abstract[88]	new[83]|new[84]|new[88]	_	_
10-25	1765-1766	,	_	_	_	_
10-26	1767-1769	it	event	giv	coref	11-4
10-27	1770-1780	represents	_	_	_	_
10-28	1781-1783	an	abstract[90]	new[90]	_	_
10-29	1784-1793	important	abstract[90]	new[90]	_	_
10-30	1794-1801	medical	abstract[90]	new[90]	_	_
10-31	1802-1811	challenge	abstract[90]	new[90]	_	_
10-32	1812-1814	in	abstract[90]	new[90]	_	_
10-33	1815-1819	term	abstract[90]|abstract[91]	new[90]|new[91]	_	_
10-34	1820-1822	of	abstract[90]|abstract[91]	new[90]|new[91]	_	_
10-35	1823-1832	diagnosis	abstract[90]|abstract[91]|abstract	new[90]|new[91]|new	_	_
10-36	1833-1836	and	abstract[90]|abstract[91]	new[90]|new[91]	_	_
10-37	1837-1846	treatment	abstract[90]|abstract[91]|event	new[90]|new[91]|new	_	_
10-38	1847-1848	.	_	_	_	_

#Text=The pathogenesis of IBS remains unclear , with several factors supposed to be involved , including environmental and host factors such as psychosocial stressors , food intolerance , antibiotics , enteric infections , altered pain perception , altered brain – gut interactions , dysbiosis ( imbalance within the bacterial community ) , increased intestinal permeability , increased gut mucosal immune activation and visceral hypersensitivity .
11-1	1849-1852	The	abstract[94]	new[94]	coref	12-16[125_94]
11-2	1853-1865	pathogenesis	abstract[94]	new[94]	_	_
11-3	1866-1868	of	abstract[94]	new[94]	_	_
11-4	1869-1872	IBS	abstract[94]|event	new[94]|giv	coref	12-19
11-5	1873-1880	remains	_	_	_	_
11-6	1881-1888	unclear	_	_	_	_
11-7	1889-1890	,	_	_	_	_
11-8	1891-1895	with	_	_	_	_
11-9	1896-1903	several	abstract[96]	new[96]	coref	11-17[97_96]
11-10	1904-1911	factors	abstract[96]	new[96]	_	_
11-11	1912-1920	supposed	_	_	_	_
11-12	1921-1923	to	_	_	_	_
11-13	1924-1926	be	_	_	_	_
11-14	1927-1935	involved	_	_	_	_
11-15	1936-1937	,	_	_	_	_
11-16	1938-1947	including	_	_	_	_
11-17	1948-1961	environmental	abstract[97]	giv[97]	coref	26-7[245_97]
11-18	1962-1965	and	abstract[97]	giv[97]	_	_
11-19	1966-1970	host	abstract[97]	giv[97]	_	_
11-20	1971-1978	factors	abstract[97]	giv[97]	_	_
11-21	1979-1983	such	abstract[97]	giv[97]	_	_
11-22	1984-1986	as	abstract[97]	giv[97]	_	_
11-23	1987-1999	psychosocial	abstract[97]|abstract[98]	giv[97]|new[98]	_	_
11-24	2000-2009	stressors	abstract[97]|abstract[98]	giv[97]|new[98]	_	_
11-25	2010-2011	,	abstract[97]	giv[97]	_	_
11-26	2012-2016	food	abstract[97]|substance|abstract[100]	giv[97]|new|new[100]	_	_
11-27	2017-2028	intolerance	abstract[97]|abstract[100]	giv[97]|new[100]	_	_
11-28	2029-2030	,	abstract[97]	giv[97]	_	_
11-29	2031-2042	antibiotics	abstract[97]|substance	giv[97]|new	_	_
11-30	2043-2044	,	abstract[97]	giv[97]	_	_
11-31	2045-2052	enteric	abstract[97]|object|abstract[103]	giv[97]|new|new[103]	_	_
11-32	2053-2063	infections	abstract[97]|abstract[103]	giv[97]|new[103]	_	_
11-33	2064-2065	,	abstract[97]	giv[97]	_	_
11-34	2066-2073	altered	abstract[97]|abstract[105]	giv[97]|new[105]	_	_
11-35	2074-2078	pain	abstract[97]|abstract|abstract[105]	giv[97]|giv|new[105]	_	_
11-36	2079-2089	perception	abstract[97]|abstract[105]	giv[97]|new[105]	_	_
11-37	2090-2091	,	abstract[97]	giv[97]	_	_
11-38	2092-2099	altered	abstract[97]|object[106]	giv[97]|new[106]	coref	12-11[0_106]
11-39	2100-2105	brain	abstract[97]|object[106]	giv[97]|new[106]	_	_
11-40	2106-2107	–	abstract[97]	giv[97]	_	_
11-41	2108-2111	gut	abstract[97]|abstract|abstract[108]	giv[97]|giv|giv[108]	coref|coref	12-8|12-13[124_108]
11-42	2112-2124	interactions	abstract[97]|abstract[108]	giv[97]|giv[108]	_	_
11-43	2125-2126	,	abstract[97]|abstract[108]	giv[97]|giv[108]	_	_
11-44	2127-2136	dysbiosis	abstract[97]|abstract[108]|abstract	giv[97]|giv[108]|new	_	_
11-45	2137-2138	(	abstract[97]	giv[97]	_	_
11-46	2139-2148	imbalance	abstract[97]|abstract[110]	giv[97]|new[110]	_	_
11-47	2149-2155	within	abstract[97]|abstract[110]	giv[97]|new[110]	_	_
11-48	2156-2159	the	abstract[97]|abstract[110]|abstract[112]	giv[97]|new[110]|giv[112]	_	_
11-49	2160-2169	bacterial	abstract[97]|abstract[110]|substance|abstract[112]	giv[97]|new[110]|new|giv[112]	_	_
11-50	2170-2179	community	abstract[97]|abstract[110]|abstract[112]	giv[97]|new[110]|giv[112]	_	_
11-51	2180-2181	)	abstract[97]	giv[97]	_	_
11-52	2182-2183	,	abstract[97]	giv[97]	_	_
11-53	2184-2193	increased	abstract[97]|abstract[113]	giv[97]|new[113]	_	_
11-54	2194-2204	intestinal	abstract[97]|abstract[113]	giv[97]|new[113]	_	_
11-55	2205-2217	permeability	abstract[97]|abstract[113]	giv[97]|new[113]	_	_
11-56	2218-2219	,	abstract[97]	giv[97]	_	_
11-57	2220-2229	increased	abstract[97]	giv[97]	_	_
11-58	2230-2233	gut	abstract[97]	giv[97]	_	_
11-59	2234-2241	mucosal	abstract[97]|abstract[115]	giv[97]|new[115]	_	_
11-60	2242-2248	immune	abstract[97]|abstract|abstract[115]	giv[97]|new|new[115]	_	_
11-61	2249-2259	activation	abstract[97]|abstract[115]	giv[97]|new[115]	_	_
11-62	2260-2263	and	abstract[97]	giv[97]	_	_
11-63	2264-2272	visceral	abstract[97]|abstract[116]	giv[97]|new[116]	_	_
11-64	2273-2289	hypersensitivity	abstract[97]|abstract[116]	giv[97]|new[116]	_	_
11-65	2290-2291	.	_	_	_	_

#Text=In recent years , the relationship between gut microbiota and brain – gut interactions in the pathogenesis of IBS has become a key topic in clinical and biomedical research .
12-1	2292-2294	In	_	_	_	_
12-2	2295-2301	recent	time[117]	new[117]	_	_
12-3	2302-2307	years	time[117]	new[117]	_	_
12-4	2308-2309	,	_	_	_	_
12-5	2310-2313	the	abstract[118]	new[118]	_	_
12-6	2314-2326	relationship	abstract[118]	new[118]	_	_
12-7	2327-2334	between	abstract[118]	new[118]	_	_
12-8	2335-2338	gut	abstract[118]|abstract|object[120]|abstract[121]	new[118]|giv|giv[120]|giv[121]	coref|coref	12-13|14-32[140_120]
12-9	2339-2349	microbiota	abstract[118]|object[120]|abstract[121]	new[118]|giv[120]|giv[121]	_	_
12-10	2350-2353	and	abstract[118]|abstract[121]	new[118]|giv[121]	_	_
12-11	2354-2359	brain	abstract[118]|abstract[121]|object	new[118]|giv[121]|giv	coref	14-18
12-12	2360-2361	–	_	_	_	_
12-13	2362-2365	gut	abstract|abstract[124]	giv|giv[124]	coref	14-15[134_0]
12-14	2366-2378	interactions	abstract[124]	giv[124]	_	_
12-15	2379-2381	in	abstract[124]	giv[124]	_	_
12-16	2382-2385	the	abstract[124]|abstract[125]	giv[124]|giv[125]	coref	15-8[147_125]
12-17	2386-2398	pathogenesis	abstract[124]|abstract[125]	giv[124]|giv[125]	_	_
12-18	2399-2401	of	abstract[124]|abstract[125]	giv[124]|giv[125]	_	_
12-19	2402-2405	IBS	abstract[124]|abstract[125]|abstract	giv[124]|giv[125]|giv	coref	14-42
12-20	2406-2409	has	_	_	_	_
12-21	2410-2416	become	_	_	_	_
12-22	2417-2418	a	_	_	_	_
12-23	2419-2422	key	_	_	_	_
12-24	2423-2428	topic	_	_	_	_
12-25	2429-2431	in	_	_	_	_
12-26	2432-2440	clinical	abstract[127]	new[127]	_	_
12-27	2441-2444	and	abstract[127]	new[127]	_	_
12-28	2445-2455	biomedical	abstract[127]	new[127]	_	_
12-29	2456-2464	research	abstract[127]	new[127]	_	_
12-30	2465-2466	.	_	_	_	_

#Text=This issue has been accurately discussed in a recent review by Quigley .
13-1	2467-2471	This	abstract[128]	new[128]	_	_
13-2	2472-2477	issue	abstract[128]	new[128]	_	_
13-3	2478-2481	has	_	_	_	_
13-4	2482-2486	been	_	_	_	_
13-5	2487-2497	accurately	_	_	_	_
13-6	2498-2507	discussed	_	_	_	_
13-7	2508-2510	in	_	_	_	_
13-8	2511-2512	a	abstract[129]	new[129]	_	_
13-9	2513-2519	recent	abstract[129]	new[129]	_	_
13-10	2520-2526	review	abstract[129]	new[129]	_	_
13-11	2527-2529	by	_	_	_	_
13-12	2530-2537	Quigley	person	new	_	_
13-13	2538-2539	.	_	_	_	_

#Text=Beginning with an excursus on the historical steps that led to the definition of the gut – brain axis , the author discussed the modern theory that postulates the involvement of gut microbiota in both the gut – brain axis and IBS .
14-1	2540-2549	Beginning	_	_	_	_
14-2	2550-2554	with	_	_	_	_
14-3	2555-2557	an	abstract[131]	new[131]	_	_
14-4	2558-2566	excursus	abstract[131]	new[131]	_	_
14-5	2567-2569	on	abstract[131]	new[131]	_	_
14-6	2570-2573	the	abstract[131]|abstract[132]	new[131]|new[132]	_	_
14-7	2574-2584	historical	abstract[131]|abstract[132]	new[131]|new[132]	_	_
14-8	2585-2590	steps	abstract[131]|abstract[132]	new[131]|new[132]	_	_
14-9	2591-2595	that	_	_	_	_
14-10	2596-2599	led	_	_	_	_
14-11	2600-2602	to	_	_	_	_
14-12	2603-2606	the	abstract[133]	new[133]	_	_
14-13	2607-2617	definition	abstract[133]	new[133]	_	_
14-14	2618-2620	of	abstract[133]	new[133]	_	_
14-15	2621-2624	the	abstract[133]|abstract[134]	new[133]|giv[134]	appos	14-18[136_134]
14-16	2625-2628	gut	abstract[133]|abstract[134]	new[133]|giv[134]	_	_
14-17	2629-2630	–	_	_	_	_
14-18	2631-2636	brain	object|abstract[136]	giv|giv[136]	coref|coref	14-35[141_136]|14-39
14-19	2637-2641	axis	abstract[136]	giv[136]	_	_
14-20	2642-2643	,	_	_	_	_
14-21	2644-2647	the	person[137]	new[137]	_	_
14-22	2648-2654	author	person[137]	new[137]	_	_
14-23	2655-2664	discussed	_	_	_	_
14-24	2665-2668	the	abstract[138]	new[138]	coref	15-5[146_138]
14-25	2669-2675	modern	abstract[138]	new[138]	_	_
14-26	2676-2682	theory	abstract[138]	new[138]	_	_
14-27	2683-2687	that	_	_	_	_
14-28	2688-2698	postulates	_	_	_	_
14-29	2699-2702	the	abstract[139]	new[139]	_	_
14-30	2703-2714	involvement	abstract[139]	new[139]	_	_
14-31	2715-2717	of	abstract[139]	new[139]	_	_
14-32	2718-2721	gut	abstract[139]|object[140]	new[139]|giv[140]	coref	17-11[0_140]
14-33	2722-2732	microbiota	abstract[139]|object[140]	new[139]|giv[140]	_	_
14-34	2733-2735	in	abstract[139]|object[140]	new[139]|giv[140]	_	_
14-35	2736-2740	both	abstract[139]|object[140]|abstract[141]	new[139]|giv[140]|giv[141]	appos	14-39[143_141]
14-36	2741-2744	the	abstract[139]|object[140]|abstract[141]	new[139]|giv[140]|giv[141]	_	_
14-37	2745-2748	gut	abstract[139]|object[140]|abstract[141]	new[139]|giv[140]|giv[141]	_	_
14-38	2749-2750	–	_	_	_	_
14-39	2751-2756	brain	object|abstract[143]	giv|giv[143]	coref	15-37[0_143]
14-40	2757-2761	axis	abstract[143]	giv[143]	_	_
14-41	2762-2765	and	abstract[143]	giv[143]	_	_
14-42	2766-2769	IBS	abstract[143]|abstract	giv[143]|giv	coref	15-11
14-43	2770-2771	.	_	_	_	_

#Text=On the basis of this theory , the pathogenesis of IBS would be related to the action of central stimuli , such as stress , that could disrupt mucosal immunity , reduce microbial diversity and alter gut barrier function , leading to gut dysfunction .
15-1	2772-2774	On	_	_	_	_
15-2	2775-2778	the	abstract[145]	new[145]	_	_
15-3	2779-2784	basis	abstract[145]	new[145]	_	_
15-4	2785-2787	of	abstract[145]	new[145]	_	_
15-5	2788-2792	this	abstract[145]|abstract[146]	new[145]|giv[146]	_	_
15-6	2793-2799	theory	abstract[145]|abstract[146]	new[145]|giv[146]	_	_
15-7	2800-2801	,	_	_	_	_
15-8	2802-2805	the	abstract[147]	giv[147]	_	_
15-9	2806-2818	pathogenesis	abstract[147]	giv[147]	_	_
15-10	2819-2821	of	abstract[147]	giv[147]	_	_
15-11	2822-2825	IBS	abstract[147]|abstract	giv[147]|giv	coref	17-16
15-12	2826-2831	would	_	_	_	_
15-13	2832-2834	be	_	_	_	_
15-14	2835-2842	related	_	_	_	_
15-15	2843-2845	to	_	_	_	_
15-16	2846-2849	the	abstract[149]	new[149]	_	_
15-17	2850-2856	action	abstract[149]	new[149]	_	_
15-18	2857-2859	of	abstract[149]	new[149]	_	_
15-19	2860-2867	central	abstract[149]|abstract[150]	new[149]|new[150]	_	_
15-20	2868-2875	stimuli	abstract[149]|abstract[150]	new[149]|new[150]	_	_
15-21	2876-2877	,	abstract[149]	new[149]	_	_
15-22	2878-2882	such	abstract[149]	new[149]	_	_
15-23	2883-2885	as	abstract[149]	new[149]	_	_
15-24	2886-2892	stress	abstract[149]|abstract	new[149]|new	_	_
15-25	2893-2894	,	_	_	_	_
15-26	2895-2899	that	_	_	_	_
15-27	2900-2905	could	_	_	_	_
15-28	2906-2913	disrupt	_	_	_	_
15-29	2914-2921	mucosal	object[152]	new[152]	_	_
15-30	2922-2930	immunity	object[152]	new[152]	_	_
15-31	2931-2932	,	_	_	_	_
15-32	2933-2939	reduce	_	_	_	_
15-33	2940-2949	microbial	abstract[153]	new[153]	coref	19-9[185_153]
15-34	2950-2959	diversity	abstract[153]	new[153]	_	_
15-35	2960-2963	and	_	_	_	_
15-36	2964-2969	alter	_	_	_	_
15-37	2970-2973	gut	abstract|abstract[156]	giv|new[156]	coref	19-3[182_0]
15-38	2974-2981	barrier	object|abstract[156]	new|new[156]	coref	21-9[211_0]
15-39	2982-2990	function	abstract[156]	new[156]	_	_
15-40	2991-2992	,	_	_	_	_
15-41	2993-3000	leading	_	_	_	_
15-42	3001-3003	to	_	_	_	_
15-43	3004-3007	gut	_	_	_	_
15-44	3008-3019	dysfunction	abstract	new	_	_
15-45	3020-3021	.	_	_	_	_

#Text=Although much work still needs to be done , there is evidence to support this pathogenetic model .
16-1	3022-3030	Although	_	_	_	_
16-2	3031-3035	much	abstract[158]	new[158]	_	_
16-3	3036-3040	work	abstract[158]	new[158]	_	_
16-4	3041-3046	still	_	_	_	_
16-5	3047-3052	needs	_	_	_	_
16-6	3053-3055	to	_	_	_	_
16-7	3056-3058	be	_	_	_	_
16-8	3059-3063	done	_	_	_	_
16-9	3064-3065	,	_	_	_	_
16-10	3066-3071	there	_	_	_	_
16-11	3072-3074	is	_	_	_	_
16-12	3075-3083	evidence	abstract	new	coref	27-1[248_0]
16-13	3084-3086	to	_	_	_	_
16-14	3087-3094	support	_	_	_	_
16-15	3095-3099	this	abstract[160]	new[160]	ana	17-3[0_160]
16-16	3100-3112	pathogenetic	abstract[160]	new[160]	_	_
16-17	3113-3118	model	abstract[160]	new[160]	_	_
16-18	3119-3120	.	_	_	_	_

#Text=First , it has been shown that fecal and colonic microbiota compositions in patients with IBS are different compared to healthy subjects .
17-1	3121-3126	First	_	_	_	_
17-2	3127-3128	,	_	_	_	_
17-3	3129-3131	it	abstract	giv	_	_
17-4	3132-3135	has	_	_	_	_
17-5	3136-3140	been	_	_	_	_
17-6	3141-3146	shown	_	_	_	_
17-7	3147-3151	that	_	_	_	_
17-8	3152-3157	fecal	abstract	new	_	_
17-9	3158-3161	and	_	_	_	_
17-10	3162-3169	colonic	abstract|abstract[165]	new|new[165]	_	_
17-11	3170-3180	microbiota	object|abstract[165]	giv|new[165]	coref	19-6
17-12	3181-3193	compositions	abstract[165]	new[165]	_	_
17-13	3194-3196	in	abstract[165]	new[165]	_	_
17-14	3197-3205	patients	abstract[165]|person[166]	new[165]|new[166]	coref	18-32[181_166]
17-15	3206-3210	with	abstract[165]|person[166]	new[165]|new[166]	_	_
17-16	3211-3214	IBS	abstract[165]|person[166]|abstract	new[165]|new[166]|giv	coref	18-32
17-17	3215-3218	are	_	_	_	_
17-18	3219-3228	different	_	_	_	_
17-19	3229-3237	compared	_	_	_	_
17-20	3238-3240	to	_	_	_	_
17-21	3241-3248	healthy	person[168]	new[168]	_	_
17-22	3249-3257	subjects	person[168]	new[168]	_	_
17-23	3258-3259	.	_	_	_	_

#Text=For example , the count of gene copies or the number of colony forming units of Lactobacilli and Bifidobacteria are compromised while those of Escherichia coli and Enterobacter are increased in IBS patients .
18-1	3260-3263	For	_	_	_	_
18-2	3264-3271	example	_	_	_	_
18-3	3272-3273	,	_	_	_	_
18-4	3274-3277	the	quantity[169]	new[169]	_	_
18-5	3278-3283	count	quantity[169]	new[169]	_	_
18-6	3284-3286	of	quantity[169]	new[169]	_	_
18-7	3287-3291	gene	quantity[169]|abstract|quantity[171]	new[169]|giv|new[171]	_	_
18-8	3292-3298	copies	quantity[169]|quantity[171]	new[169]|new[171]	_	_
18-9	3299-3301	or	_	_	_	_
18-10	3302-3305	the	quantity[172]	new[172]	_	_
18-11	3306-3312	number	quantity[172]	new[172]	_	_
18-12	3313-3315	of	quantity[172]	new[172]	_	_
18-13	3316-3322	colony	quantity[172]|abstract	new[172]|new	ana	18-23[177_0]
18-14	3323-3330	forming	_	_	_	_
18-15	3331-3336	units	organization[174]	new[174]	_	_
18-16	3337-3339	of	organization[174]	new[174]	_	_
18-17	3340-3352	Lactobacilli	organization[174]|substance	new[174]|new	_	_
18-18	3353-3356	and	organization[174]	new[174]	_	_
18-19	3357-3371	Bifidobacteria	organization[174]|substance	new[174]|new	_	_
18-20	3372-3375	are	_	_	_	_
18-21	3376-3387	compromised	_	_	_	_
18-22	3388-3393	while	_	_	_	_
18-23	3394-3399	those	abstract[177]	giv[177]	_	_
18-24	3400-3402	of	abstract[177]	giv[177]	_	_
18-25	3403-3414	Escherichia	abstract[177]|abstract	giv[177]|new	_	_
18-26	3415-3419	coli	abstract[177]	giv[177]	_	_
18-27	3420-3423	and	abstract[177]	giv[177]	_	_
18-28	3424-3436	Enterobacter	abstract[177]|person	giv[177]|new	_	_
18-29	3437-3440	are	_	_	_	_
18-30	3441-3450	increased	_	_	_	_
18-31	3451-3453	in	_	_	_	_
18-32	3454-3457	IBS	abstract|person[181]	giv|giv[181]	coref|coref	19-28|27-9[250_181]
18-33	3458-3466	patients	person[181]	giv[181]	_	_
18-34	3467-3468	.	_	_	_	_

#Text=Furthermore , a specific gut microbiota signature ( low microbial diversity , absence of Methanobacteriales and enrichment with Bacteroides ) could be linked to the severity of IBS .
19-1	3469-3480	Furthermore	_	_	_	_
19-2	3481-3482	,	_	_	_	_
19-3	3483-3484	a	object[182]	giv[182]	appos	19-6[184_182]
19-4	3485-3493	specific	object[182]	giv[182]	_	_
19-5	3494-3497	gut	object[182]	giv[182]	_	_
19-6	3498-3508	microbiota	object|object[184]	giv|giv[184]	coref|coref	20-25|22-20[220_184]
19-7	3509-3518	signature	object[184]	giv[184]	_	_
19-8	3519-3520	(	_	_	_	_
19-9	3521-3524	low	abstract[185]	giv[185]	_	_
19-10	3525-3534	microbial	abstract[185]	giv[185]	_	_
19-11	3535-3544	diversity	abstract[185]	giv[185]	_	_
19-12	3545-3546	,	_	_	_	_
19-13	3547-3554	absence	abstract[186]	new[186]	_	_
19-14	3555-3557	of	abstract[186]	new[186]	_	_
19-15	3558-3576	Methanobacteriales	abstract[186]|plant	new[186]|new	_	_
19-16	3577-3580	and	abstract[186]	new[186]	_	_
19-17	3581-3591	enrichment	abstract[186]|abstract[188]	new[186]|new[188]	_	_
19-18	3592-3596	with	abstract[186]|abstract[188]	new[186]|new[188]	_	_
19-19	3597-3608	Bacteroides	abstract[186]|abstract[188]|substance	new[186]|new[188]|new	_	_
19-20	3609-3610	)	_	_	_	_
19-21	3611-3616	could	_	_	_	_
19-22	3617-3619	be	_	_	_	_
19-23	3620-3626	linked	_	_	_	_
19-24	3627-3629	to	_	_	_	_
19-25	3630-3633	the	abstract[190]	new[190]	_	_
19-26	3634-3642	severity	abstract[190]	new[190]	_	_
19-27	3643-3645	of	abstract[190]	new[190]	_	_
19-28	3646-3649	IBS	abstract[190]|event	new[190]|giv	coref	20-15
19-29	3650-3651	.	_	_	_	_

#Text=Second , the benefits reported in some studies after antibiotic or probiotic administration on IBS symptoms are proof in favor of a role of microbiota in the pathogenesis of this disease . Data from animal models provides a plausible explanation for this benefit .
20-1	3652-3658	Second	_	_	_	_
20-2	3659-3660	,	_	_	_	_
20-3	3661-3664	the	abstract[192]	new[192]	coref	20-18[199_192]
20-4	3665-3673	benefits	abstract[192]	new[192]	_	_
20-5	3674-3682	reported	_	_	_	_
20-6	3683-3685	in	_	_	_	_
20-7	3686-3690	some	event[193]	new[193]	_	_
20-8	3691-3698	studies	event[193]	new[193]	_	_
20-9	3699-3704	after	event[193]	new[193]	_	_
20-10	3705-3715	antibiotic	event[193]|substance	new[193]|new	coref	23-9
20-11	3716-3718	or	event[193]	new[193]	_	_
20-12	3719-3728	probiotic	event[193]|substance|organization[196]	new[193]|new|new[196]	_	_
20-13	3729-3743	administration	event[193]|organization[196]	new[193]|new[196]	_	_
20-14	3744-3746	on	event[193]|organization[196]	new[193]|new[196]	_	_
20-15	3747-3750	IBS	event[193]|organization[196]|abstract|abstract[198]	new[193]|new[196]|giv|new[198]	coref|coref	23-20|23-18[231_198]
20-16	3751-3759	symptoms	event[193]|organization[196]|abstract[198]	new[193]|new[196]|new[198]	_	_
20-17	3760-3763	are	_	_	_	_
20-18	3764-3769	proof	abstract[199]	giv[199]	_	_
20-19	3770-3772	in	abstract[199]	giv[199]	_	_
20-20	3773-3778	favor	abstract[199]|abstract[200]	giv[199]|new[200]	_	_
20-21	3779-3781	of	abstract[199]|abstract[200]	giv[199]|new[200]	_	_
20-22	3782-3783	a	abstract[199]|abstract[200]|abstract[201]	giv[199]|new[200]|new[201]	coref	25-7[238_201]
20-23	3784-3788	role	abstract[199]|abstract[200]|abstract[201]	giv[199]|new[200]|new[201]	_	_
20-24	3789-3791	of	abstract[199]|abstract[200]|abstract[201]	giv[199]|new[200]|new[201]	_	_
20-25	3792-3802	microbiota	abstract[199]|abstract[200]|abstract[201]|object	giv[199]|new[200]|new[201]|giv	coref	25-3[237_0]
20-26	3803-3805	in	abstract[199]|abstract[200]|abstract[201]	giv[199]|new[200]|new[201]	_	_
20-27	3806-3809	the	abstract[199]|abstract[200]|abstract[201]|abstract[203]	giv[199]|new[200]|new[201]|new[203]	_	_
20-28	3810-3822	pathogenesis	abstract[199]|abstract[200]|abstract[201]|abstract[203]	giv[199]|new[200]|new[201]|new[203]	_	_
20-29	3823-3825	of	abstract[199]|abstract[200]|abstract[201]|abstract[203]	giv[199]|new[200]|new[201]|new[203]	_	_
20-30	3826-3830	this	abstract[199]|abstract[200]|abstract[201]|abstract[203]|abstract[204]	giv[199]|new[200]|new[201]|new[203]|new[204]	_	_
20-31	3831-3838	disease	abstract[199]|abstract[200]|abstract[201]|abstract[203]|abstract[204]	giv[199]|new[200]|new[201]|new[203]|new[204]	_	_
20-32	3839-3840	.	_	_	_	_
20-33	3841-3845	Data	abstract[205]	new[205]	_	_
20-34	3846-3850	from	abstract[205]	new[205]	_	_
20-35	3851-3857	animal	abstract[205]|abstract[206]	new[205]|new[206]	_	_
20-36	3858-3864	models	abstract[205]|abstract[206]	new[205]|new[206]	_	_
20-37	3865-3873	provides	_	_	_	_
20-38	3874-3875	a	abstract[207]	new[207]	_	_
20-39	3876-3885	plausible	abstract[207]	new[207]	_	_
20-40	3886-3897	explanation	abstract[207]	new[207]	_	_
20-41	3898-3901	for	abstract[207]	new[207]	_	_
20-42	3902-3906	this	abstract[207]|abstract[208]	new[207]|new[208]	ana	21-1[0_208]
20-43	3907-3914	benefit	abstract[207]|abstract[208]	new[207]|new[208]	_	_
20-44	3915-3916	.	_	_	_	_

#Text=It has been shown that probiotics can enhance the intestinal mucosal barrier and increase the number of butyrate-producing bacteria .
21-1	3917-3919	It	abstract	giv	_	_
21-2	3920-3923	has	_	_	_	_
21-3	3924-3928	been	_	_	_	_
21-4	3929-3934	shown	_	_	_	_
21-5	3935-3939	that	_	_	_	_
21-6	3940-3950	probiotics	substance	new	coref	23-12
21-7	3951-3954	can	_	_	_	_
21-8	3955-3962	enhance	_	_	_	_
21-9	3963-3966	the	object[211]	giv[211]	_	_
21-10	3967-3977	intestinal	object[211]	giv[211]	_	_
21-11	3978-3985	mucosal	object[211]	giv[211]	_	_
21-12	3986-3993	barrier	object[211]	giv[211]	_	_
21-13	3994-3997	and	_	_	_	_
21-14	3998-4006	increase	_	_	_	_
21-15	4007-4010	the	quantity[212]	new[212]	_	_
21-16	4011-4017	number	quantity[212]	new[212]	_	_
21-17	4018-4020	of	quantity[212]	new[212]	_	_
21-18	4021-4039	butyrate-producing	quantity[212]|animal[213]	new[212]|giv[213]	coref	29-18[277_213]
21-19	4040-4048	bacteria	quantity[212]|animal[213]	new[212]|giv[213]	_	_
21-20	4049-4050	.	_	_	_	_

#Text=The augmented production of short-chain fatty acids ( SCFAs ) , such as butyric and acetic acid , acidizes the gut and facilitates the beneficial colonization of Lactobacillus and Bifidobacterium species .
22-1	4051-4054	The	abstract[214]	new[214]	_	_
22-2	4055-4064	augmented	abstract[214]	new[214]	_	_
22-3	4065-4075	production	abstract[214]	new[214]	_	_
22-4	4076-4078	of	abstract[214]	new[214]	_	_
22-5	4079-4090	short-chain	abstract[214]|abstract[215]	new[214]|new[215]	appos	22-9[0_215]
22-6	4091-4096	fatty	abstract[214]|abstract[215]	new[214]|new[215]	_	_
22-7	4097-4102	acids	abstract[214]|abstract[215]	new[214]|new[215]	_	_
22-8	4103-4104	(	_	_	_	_
22-9	4105-4110	SCFAs	abstract	giv	coref	25-20
22-10	4111-4112	)	_	_	_	_
22-11	4113-4114	,	_	_	_	_
22-12	4115-4119	such	_	_	_	_
22-13	4120-4122	as	_	_	_	_
22-14	4123-4130	butyric	substance	new	_	_
22-15	4131-4134	and	_	_	_	_
22-16	4135-4141	acetic	abstract|substance[219]	new|new[219]	_	_
22-17	4142-4146	acid	substance[219]	new[219]	_	_
22-18	4147-4148	,	_	_	_	_
22-19	4149-4157	acidizes	_	_	_	_
22-20	4158-4161	the	object[220]	giv[220]	coref	25-4[0_220]
22-21	4162-4165	gut	object[220]	giv[220]	_	_
22-22	4166-4169	and	_	_	_	_
22-23	4170-4181	facilitates	_	_	_	_
22-24	4182-4185	the	abstract[221]	new[221]	_	_
22-25	4186-4196	beneficial	abstract[221]	new[221]	_	_
22-26	4197-4209	colonization	abstract[221]	new[221]	_	_
22-27	4210-4212	of	abstract[221]	new[221]	_	_
22-28	4213-4226	Lactobacillus	abstract[221]|plant|plant[223]	new[221]|new|giv[223]	_	_
22-29	4227-4230	and	abstract[221]|plant[223]	new[221]|giv[223]	_	_
22-30	4231-4246	Bifidobacterium	abstract[221]|plant[223]	new[221]|giv[223]	_	_
22-31	4247-4254	species	abstract[221]|plant[223]	new[221]|giv[223]	_	_
22-32	4255-4256	.	_	_	_	_

#Text=Whatever the precise mechanism , the poorly absorbed antibiotic rifaximin and probiotics or prebiotics provided relief against the cardinal IBS symptoms .
23-1	4257-4265	Whatever	_	_	_	_
23-2	4266-4269	the	abstract[224]	new[224]	_	_
23-3	4270-4277	precise	abstract[224]	new[224]	_	_
23-4	4278-4287	mechanism	abstract[224]	new[224]	_	_
23-5	4288-4289	,	_	_	_	_
23-6	4290-4293	the	substance[226]	new[226]	_	_
23-7	4294-4300	poorly	substance[226]	new[226]	_	_
23-8	4301-4309	absorbed	substance[226]	new[226]	_	_
23-9	4310-4320	antibiotic	substance|substance[226]	giv|new[226]	_	_
23-10	4321-4330	rifaximin	substance[226]	new[226]	_	_
23-11	4331-4334	and	_	_	_	_
23-12	4335-4345	probiotics	substance	giv	coref	24-11
23-13	4346-4348	or	_	_	_	_
23-14	4349-4359	prebiotics	substance	new	_	_
23-15	4360-4368	provided	_	_	_	_
23-16	4369-4375	relief	abstract	new	coref	28-25[270_0]
23-17	4376-4383	against	_	_	_	_
23-18	4384-4387	the	abstract[231]	giv[231]	_	_
23-19	4388-4396	cardinal	abstract[231]	giv[231]	_	_
23-20	4397-4400	IBS	abstract|abstract[231]	giv|giv[231]	coref	27-11
23-21	4401-4409	symptoms	abstract[231]	giv[231]	_	_
23-22	4410-4411	.	_	_	_	_

#Text=For these reasons , recent international guidelines suggest to prescribe probiotics in this context .
24-1	4412-4415	For	_	_	_	_
24-2	4416-4421	these	abstract[232]	new[232]	_	_
24-3	4422-4429	reasons	abstract[232]	new[232]	_	_
24-4	4430-4431	,	_	_	_	_
24-5	4432-4438	recent	abstract[233]	new[233]	_	_
24-6	4439-4452	international	abstract[233]	new[233]	_	_
24-7	4453-4463	guidelines	abstract[233]	new[233]	_	_
24-8	4464-4471	suggest	_	_	_	_
24-9	4472-4474	to	_	_	_	_
24-10	4475-4484	prescribe	_	_	_	_
24-11	4485-4495	probiotics	substance	giv	_	_
24-12	4496-4498	in	_	_	_	_
24-13	4499-4503	this	abstract[235]	new[235]	_	_
24-14	4504-4511	context	abstract[235]	new[235]	_	_
24-15	4512-4513	.	_	_	_	_

#Text=Third , the gut microbiota plays a key role in digestion , absorption and synthesis of metabolites such as SCFAs .
25-1	4514-4519	Third	_	_	_	_
25-2	4520-4521	,	_	_	_	_
25-3	4522-4525	the	object[237]	giv[237]	coref	27-19[0_237]
25-4	4526-4529	gut	abstract|object[237]	giv|giv[237]	coref	27-31
25-5	4530-4540	microbiota	object[237]	giv[237]	_	_
25-6	4541-4546	plays	_	_	_	_
25-7	4547-4548	a	abstract[238]	giv[238]	_	_
25-8	4549-4552	key	abstract[238]	giv[238]	_	_
25-9	4553-4557	role	abstract[238]	giv[238]	_	_
25-10	4558-4560	in	abstract[238]	giv[238]	_	_
25-11	4561-4570	digestion	abstract[238]|abstract	giv[238]|new	_	_
25-12	4571-4572	,	abstract[238]	giv[238]	_	_
25-13	4573-4583	absorption	abstract[238]|abstract	giv[238]|new	_	_
25-14	4584-4587	and	abstract[238]	giv[238]	_	_
25-15	4588-4597	synthesis	abstract[238]|abstract[241]	giv[238]|new[241]	_	_
25-16	4598-4600	of	abstract[238]|abstract[241]	giv[238]|new[241]	_	_
25-17	4601-4612	metabolites	abstract[238]|abstract[241]|substance[242]	giv[238]|new[241]|new[242]	coref	26-1[244_242]
25-18	4613-4617	such	abstract[238]|abstract[241]|substance[242]	giv[238]|new[241]|new[242]	_	_
25-19	4618-4620	as	abstract[238]|abstract[241]|substance[242]	giv[238]|new[241]|new[242]	_	_
25-20	4621-4626	SCFAs	abstract[238]|abstract[241]|substance[242]|substance	giv[238]|new[241]|new[242]|giv	_	_
25-21	4627-4628	.	_	_	_	_

#Text=These metabolites are directly associated with environmental factors such as diet and lifestyle .
26-1	4629-4634	These	substance[244]	giv[244]	_	_
26-2	4635-4646	metabolites	substance[244]	giv[244]	_	_
26-3	4647-4650	are	_	_	_	_
26-4	4651-4659	directly	_	_	_	_
26-5	4660-4670	associated	_	_	_	_
26-6	4671-4675	with	_	_	_	_
26-7	4676-4689	environmental	abstract[245]	giv[245]	_	_
26-8	4690-4697	factors	abstract[245]	giv[245]	_	_
26-9	4698-4702	such	abstract[245]	giv[245]	_	_
26-10	4703-4705	as	abstract[245]	giv[245]	_	_
26-11	4706-4710	diet	abstract[245]|abstract	giv[245]|new	coref	28-18
26-12	4711-4714	and	abstract[245]	giv[245]	_	_
26-13	4715-4724	lifestyle	abstract[245]|abstract	giv[245]|new	_	_
26-14	4725-4726	.	_	_	_	_

#Text=Growing evidence supports the concept that , in patients with IBS , specific diets could be associated to microbiota modulation , thus adding another piece of the puzzle to the gut microbiota-IBS link .
27-1	4727-4734	Growing	abstract[248]	giv[248]	_	_
27-2	4735-4743	evidence	abstract[248]	giv[248]	_	_
27-3	4744-4752	supports	_	_	_	_
27-4	4753-4756	the	abstract[249]	new[249]	_	_
27-5	4757-4764	concept	abstract[249]	new[249]	_	_
27-6	4765-4769	that	_	_	_	_
27-7	4770-4771	,	_	_	_	_
27-8	4772-4774	in	_	_	_	_
27-9	4775-4783	patients	person[250]	giv[250]	coref	28-28[272_250]
27-10	4784-4788	with	person[250]	giv[250]	_	_
27-11	4789-4792	IBS	person[250]|abstract	giv[250]|giv	coref	28-29
27-12	4793-4794	,	_	_	_	_
27-13	4795-4803	specific	abstract[252]	new[252]	coref	30-12[289_252]
27-14	4804-4809	diets	abstract[252]	new[252]	_	_
27-15	4810-4815	could	_	_	_	_
27-16	4816-4818	be	_	_	_	_
27-17	4819-4829	associated	_	_	_	_
27-18	4830-4832	to	_	_	_	_
27-19	4833-4843	microbiota	object|abstract[254]	giv|new[254]	coref	29-11
27-20	4844-4854	modulation	abstract[254]	new[254]	_	_
27-21	4855-4856	,	_	_	_	_
27-22	4857-4861	thus	_	_	_	_
27-23	4862-4868	adding	_	_	_	_
27-24	4869-4876	another	abstract[255]	new[255]	_	_
27-25	4877-4882	piece	abstract[255]	new[255]	_	_
27-26	4883-4885	of	abstract[255]	new[255]	_	_
27-27	4886-4889	the	abstract[255]|abstract[256]	new[255]|new[256]	_	_
27-28	4890-4896	puzzle	abstract[255]|abstract[256]	new[255]|new[256]	_	_
27-29	4897-4899	to	abstract[255]|abstract[256]	new[255]|new[256]	_	_
27-30	4900-4903	the	abstract[255]|abstract[256]|abstract[259]	new[255]|new[256]|new[259]	_	_
27-31	4904-4907	gut	abstract[255]|abstract[256]|abstract|abstract[259]	new[255]|new[256]|giv|new[259]	coref	30-16
27-32	4908-4922	microbiota-IBS	abstract[255]|abstract[256]|abstract|abstract[259]	new[255]|new[256]|new|new[259]	_	_
27-33	4923-4927	link	abstract[255]|abstract[256]|abstract[259]	new[255]|new[256]|new[259]	_	_
27-34	4928-4929	.	_	_	_	_

#Text=Of increasing interest is the low fermentable oligosaccharides , disaccharides , monosaccharides and polyols ( FODMAPs ) diet that leads to reduced flatulence and symptom relief in some IBS patients .
28-1	4930-4932	Of	_	_	_	_
28-2	4933-4943	increasing	substance[260]	new[260]	coref	28-5[262_260]
28-3	4944-4952	interest	substance[260]	new[260]	_	_
28-4	4953-4955	is	_	_	_	_
28-5	4956-4959	the	substance[262]	giv[262]	_	_
28-6	4960-4963	low	substance[262]	giv[262]	_	_
28-7	4964-4975	fermentable	abstract|substance[262]	new|giv[262]	_	_
28-8	4976-4992	oligosaccharides	substance[262]	giv[262]	_	_
28-9	4993-4994	,	substance[262]	giv[262]	_	_
28-10	4995-5008	disaccharides	substance[262]|substance	giv[262]|new	_	_
28-11	5009-5010	,	substance[262]	giv[262]	_	_
28-12	5011-5026	monosaccharides	substance[262]|substance	giv[262]|new	_	_
28-13	5027-5030	and	substance[262]	giv[262]	_	_
28-14	5031-5038	polyols	substance[262]|substance	giv[262]|new	_	_
28-15	5039-5040	(	substance[262]	giv[262]	_	_
28-16	5041-5048	FODMAPs	substance[262]|abstract	giv[262]|new	coref	29-44
28-17	5049-5050	)	substance[262]	giv[262]	_	_
28-18	5051-5055	diet	substance[262]|abstract	giv[262]|giv	coref	29-8[274_0]
28-19	5056-5060	that	_	_	_	_
28-20	5061-5066	leads	_	_	_	_
28-21	5067-5069	to	_	_	_	_
28-22	5070-5077	reduced	abstract[268]	new[268]	_	_
28-23	5078-5088	flatulence	abstract[268]	new[268]	_	_
28-24	5089-5092	and	_	_	_	_
28-25	5093-5100	symptom	abstract|abstract[270]	new|giv[270]	_	_
28-26	5101-5107	relief	abstract[270]	giv[270]	_	_
28-27	5108-5110	in	abstract[270]	giv[270]	_	_
28-28	5111-5115	some	abstract[270]|person[272]	giv[270]|giv[272]	coref	29-40[283_272]
28-29	5116-5119	IBS	abstract[270]|abstract|person[272]	giv[270]|giv|giv[272]	_	_
28-30	5120-5128	patients	abstract[270]|person[272]	giv[270]|giv[272]	_	_
28-31	5129-5130	.	_	_	_	_

#Text=Nevertheless , while the beneficial role of this diet on microbiota remains unclear , a reduction of commensal bacteria has been reported . Hustoft et al. have shown a reduction in fecal Actinobacteria , Bifidobacterium and Fecalibacterium prausnitzii in patients on a low FODMAPs diet .
29-1	5131-5143	Nevertheless	_	_	_	_
29-2	5144-5145	,	_	_	_	_
29-3	5146-5151	while	_	_	_	_
29-4	5152-5155	the	abstract[273]	new[273]	_	_
29-5	5156-5166	beneficial	abstract[273]	new[273]	_	_
29-6	5167-5171	role	abstract[273]	new[273]	_	_
29-7	5172-5174	of	abstract[273]	new[273]	_	_
29-8	5175-5179	this	abstract[273]|abstract[274]	new[273]|giv[274]	coref	29-42[285_274]
29-9	5180-5184	diet	abstract[273]|abstract[274]	new[273]|giv[274]	_	_
29-10	5185-5187	on	abstract[273]|abstract[274]	new[273]|giv[274]	_	_
29-11	5188-5198	microbiota	abstract[273]|abstract[274]|object	new[273]|giv[274]|giv	coref	30-16[291_0]
29-12	5199-5206	remains	_	_	_	_
29-13	5207-5214	unclear	_	_	_	_
29-14	5215-5216	,	_	_	_	_
29-15	5217-5218	a	abstract[276]	new[276]	coref	29-29[279_276]
29-16	5219-5228	reduction	abstract[276]	new[276]	_	_
29-17	5229-5231	of	abstract[276]	new[276]	_	_
29-18	5232-5241	commensal	abstract[276]|animal[277]	new[276]|giv[277]	_	_
29-19	5242-5250	bacteria	abstract[276]|animal[277]	new[276]|giv[277]	_	_
29-20	5251-5254	has	_	_	_	_
29-21	5255-5259	been	_	_	_	_
29-22	5260-5268	reported	_	_	_	_
29-23	5269-5270	.	_	_	_	_
29-24	5271-5278	Hustoft	person	new	_	_
29-25	5279-5281	et	_	_	_	_
29-26	5282-5285	al.	_	_	_	_
29-27	5286-5290	have	_	_	_	_
29-28	5291-5296	shown	_	_	_	_
29-29	5297-5298	a	abstract[279]	giv[279]	_	_
29-30	5299-5308	reduction	abstract[279]	giv[279]	_	_
29-31	5309-5311	in	abstract[279]	giv[279]	_	_
29-32	5312-5317	fecal	abstract[279]|person|animal[281]	giv[279]|new|giv[281]	_	_
29-33	5318-5332	Actinobacteria	abstract[279]|animal[281]	giv[279]|giv[281]	_	_
29-34	5333-5334	,	abstract[279]	giv[279]	_	_
29-35	5335-5350	Bifidobacterium	abstract[279]	giv[279]	_	_
29-36	5351-5354	and	abstract[279]	giv[279]	_	_
29-37	5355-5370	Fecalibacterium	abstract[279]|substance	giv[279]|new	_	_
29-38	5371-5382	prausnitzii	abstract[279]	giv[279]	_	_
29-39	5383-5385	in	_	_	_	_
29-40	5386-5394	patients	person[283]	giv[283]	_	_
29-41	5395-5397	on	person[283]	giv[283]	_	_
29-42	5398-5399	a	person[283]|abstract[285]	giv[283]|giv[285]	ana	30-1[0_285]
29-43	5400-5403	low	person[283]|abstract[285]	giv[283]|giv[285]	_	_
29-44	5404-5411	FODMAPs	person[283]|animal|abstract[285]	giv[283]|giv|giv[285]	_	_
29-45	5412-5416	diet	person[283]|abstract[285]	giv[283]|giv[285]	_	_
29-46	5417-5418	.	_	_	_	_

#Text=This warrants further investigation on the potential negative effects of “ therapeutic “ diets on gut microbiota .
30-1	5419-5423	This	abstract	giv	_	_
30-2	5424-5432	warrants	_	_	_	_
30-3	5433-5440	further	abstract[287]	new[287]	_	_
30-4	5441-5454	investigation	abstract[287]	new[287]	_	_
30-5	5455-5457	on	abstract[287]	new[287]	_	_
30-6	5458-5461	the	abstract[287]|abstract[288]	new[287]|new[288]	_	_
30-7	5462-5471	potential	abstract[287]|abstract[288]	new[287]|new[288]	_	_
30-8	5472-5480	negative	abstract[287]|abstract[288]	new[287]|new[288]	_	_
30-9	5481-5488	effects	abstract[287]|abstract[288]	new[287]|new[288]	_	_
30-10	5489-5491	of	abstract[287]|abstract[288]	new[287]|new[288]	_	_
30-11	5492-5493	“	abstract[287]|abstract[288]	new[287]|new[288]	_	_
30-12	5494-5505	therapeutic	abstract[287]|abstract[288]|abstract[289]	new[287]|new[288]|giv[289]	_	_
30-13	5506-5507	“	abstract[287]|abstract[288]|abstract[289]	new[287]|new[288]|giv[289]	_	_
30-14	5508-5513	diets	abstract[287]|abstract[288]|abstract[289]	new[287]|new[288]|giv[289]	_	_
30-15	5514-5516	on	abstract[287]|abstract[288]|abstract[289]	new[287]|new[288]|giv[289]	_	_
30-16	5517-5520	gut	abstract[287]|abstract[288]|abstract[289]|abstract|object[291]	new[287]|new[288]|giv[289]|giv|giv[291]	_	_
30-17	5521-5531	microbiota	abstract[287]|abstract[288]|abstract[289]|object[291]	new[287]|new[288]|giv[289]|giv[291]	_	_
30-18	5532-5533	.	_	_	_	_
